Management  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
fingolimod  ||| S:14 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
clinical  ||| S:28 E:37 ||| JJ
practice  ||| S:37 E:46 ||| NN
The  ||| S:46 E:50 ||| DT
efficacy  ||| S:50 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
the  ||| S:62 E:66 ||| DT
innovative  ||| S:66 E:77 ||| JJ
oral  ||| S:77 E:82 ||| JJ
drug  ||| S:82 E:87 ||| NN
fingolimod  ||| S:87 E:98 ||| NN
has  ||| S:98 E:102 ||| VBZ
been  ||| S:102 E:107 ||| VBN
proven  ||| S:107 E:114 ||| VBN
in  ||| S:114 E:117 ||| IN
the  ||| S:117 E:121 ||| DT
largest  ||| S:121 E:129 ||| JJS
study  ||| S:129 E:135 ||| NN
program  ||| S:135 E:143 ||| NN
in  ||| S:143 E:146 ||| IN
multiple  ||| S:146 E:155 ||| JJ
sclerosis  ||| S:155 E:165 ||| NNS
( ||| S:165 E:166 ||| -LRB-
MS ||| S:166 E:168 ||| NNP
)  ||| S:168 E:170 ||| -RRB-
demonstrating  ||| S:170 E:184 ||| VBZ
reduced  ||| S:184 E:192 ||| VBN
relapse  ||| S:192 E:200 ||| NNS
and  ||| S:200 E:204 ||| CC
reduced  ||| S:204 E:212 ||| JJ
disability  ||| S:212 E:223 ||| NN
progression  ||| S:223 E:235 ||| NN
in  ||| S:235 E:238 ||| IN
relapsing-remitting  ||| S:238 E:258 ||| NNP
MS  ||| S:258 E:261 ||| NNP
patients ||| S:261 E:269 ||| NNS
.  ||| S:269 E:271 ||| .
Based  ||| S:271 E:277 ||| VBN
on  ||| S:277 E:280 ||| IN
the  ||| S:280 E:284 ||| DT
extensive  ||| S:284 E:294 ||| JJ
safety  ||| S:294 E:301 ||| NN
data  ||| S:301 E:306 ||| NNS
of  ||| S:306 E:309 ||| IN
all  ||| S:309 E:313 ||| DT
clinical  ||| S:313 E:322 ||| JJ
trials  ||| S:322 E:329 ||| NNS
and  ||| S:329 E:333 ||| CC
the  ||| S:333 E:337 ||| DT
natural  ||| S:337 E:345 ||| JJ
distribution  ||| S:345 E:358 ||| NN
pattern  ||| S:358 E:366 ||| NN
of  ||| S:366 E:369 ||| IN
fingolimod  ||| S:369 E:380 ||| JJ
interacting  ||| S:380 E:392 ||| JJ
receptors  ||| S:392 E:402 ||| NNS
in  ||| S:402 E:405 ||| IN
organism ||| S:405 E:413 ||| NN
,  ||| S:413 E:415 ||| ,
careful  ||| S:415 E:423 ||| JJ
clinical  ||| S:423 E:432 ||| JJ
monitoring  ||| S:432 E:443 ||| NN
is  ||| S:443 E:446 ||| VBZ
recommend  ||| S:446 E:456 ||| VBN
and  ||| S:456 E:460 ||| CC
reviewed  ||| S:460 E:469 ||| VBN
in  ||| S:469 E:472 ||| IN
this  ||| S:472 E:477 ||| DT
paper ||| S:477 E:482 ||| NN
.  ||| S:482 E:484 ||| .
Safety  ||| S:484 E:491 ||| NNP
and  ||| S:491 E:495 ||| CC
tolerability  ||| S:495 E:508 ||| JJ
data  ||| S:508 E:513 ||| NNS
from  ||| S:513 E:518 ||| IN
clinical  ||| S:518 E:527 ||| JJ
studies  ||| S:527 E:535 ||| NNS
as  ||| S:535 E:538 ||| IN
well  ||| S:538 E:543 ||| RB
as  ||| S:543 E:546 ||| IN
current  ||| S:546 E:554 ||| JJ
post-marketing  ||| S:554 E:569 ||| JJ
experience  ||| S:569 E:580 ||| NN
present  ||| S:580 E:588 ||| NN
with  ||| S:588 E:593 ||| IN
high  ||| S:593 E:598 ||| JJ
tolerability  ||| S:598 E:611 ||| NN
and  ||| S:611 E:615 ||| CC
easy-to-perform  ||| S:615 E:631 ||| JJ
management  ||| S:631 E:642 ||| NN
of  ||| S:642 E:645 ||| IN
fingolimod ||| S:645 E:655 ||| NN
.  ||| S:655 E:657 ||| .
Here  ||| S:657 E:662 ||| RB
we  ||| S:662 E:665 ||| PRP
present  ||| S:665 E:673 ||| VBP
the  ||| S:673 E:677 ||| DT
recommended  ||| S:677 E:689 ||| JJ
management  ||| S:689 E:700 ||| NN
of  ||| S:700 E:703 ||| IN
fingolimod  ||| S:703 E:714 ||| NN
in  ||| S:714 E:717 ||| IN
clinical  ||| S:717 E:726 ||| JJ
practice  ||| S:726 E:735 ||| NN
starting  ||| S:735 E:744 ||| VBG
with  ||| S:744 E:749 ||| IN
preparatory  ||| S:749 E:761 ||| JJ
steps ||| S:761 E:766 ||| NNS
,  ||| S:766 E:768 ||| ,
first-dose  ||| S:768 E:779 ||| JJ
application  ||| S:779 E:791 ||| NN
and  ||| S:791 E:795 ||| CC
long-term  ||| S:795 E:805 ||| JJ
treatment  ||| S:805 E:815 ||| NN
period  ||| S:815 E:822 ||| NN
with  ||| S:822 E:827 ||| IN
fingolimod ||| S:827 E:837 ||| NN
.  ||| S:837 E:839 ||| .
This  ||| S:839 E:844 ||| DT
management  ||| S:844 E:855 ||| NN
of  ||| S:855 E:858 ||| IN
fingolimod  ||| S:858 E:869 ||| NN
in  ||| S:869 E:872 ||| IN
clinical  ||| S:872 E:881 ||| JJ
practice  ||| S:881 E:890 ||| NN
ensure  ||| S:890 E:897 ||| VB
a  ||| S:897 E:899 ||| DT
safe  ||| S:899 E:904 ||| JJ
treatment  ||| S:904 E:914 ||| NN
algorithm  ||| S:914 E:924 ||| VBZ
using  ||| S:924 E:930 ||| VBG
fingolimod ||| S:930 E:940 ||| NNS
.  ||| S:940 E:942 ||| .
We  ||| S:942 E:945 ||| PRP
recommend  ||| S:945 E:955 ||| VBP
documentation  ||| S:955 E:969 ||| VBN
of  ||| S:969 E:972 ||| IN
fingolimod  ||| S:972 E:983 ||| JJ
patients  ||| S:983 E:992 ||| NNS
in  ||| S:992 E:995 ||| IN
clinical  ||| S:995 E:1004 ||| JJ
registries  ||| S:1004 E:1015 ||| NN
to  ||| S:1015 E:1018 ||| TO
generate  ||| S:1018 E:1027 ||| VB
postmarketing  ||| S:1027 E:1041 ||| JJ
data  ||| S:1041 E:1046 ||| NNS
on  ||| S:1046 E:1049 ||| IN
efficacy  ||| S:1049 E:1058 ||| NN
and  ||| S:1058 E:1062 ||| CC
safety  ||| S:1062 E:1069 ||| NN
of  ||| S:1069 E:1072 ||| IN
fingoilimod ||| S:1072 E:1083 ||| NN
.  ||| S:1083 E:1085 ||| .
